Question 1

Has Matthew Gall received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $35,790 in general payments to Matthew Gall across 75 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Matthew Gall did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Matthew Gall come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Merck	36	$29,261
Bayer	10	$5,940
Incyte Corporation	2	$109
Astellas Pharma US Inc	3	$106
E.r. Squibb & Sons, L.L.C.	5	$82
Johnson & Johnson(2 entities)	2	$34
Genentech USA, Inc.	2	$33
Pfizer	2	$31
Tersera Therapeutics LLC	2	$29
Gilead	2	$28
Lilly USA, LLC	2	$26
Taiho Oncology, Inc.	1	$20
Novocure Inc.	1	$20
Secura Bio, Inc.	1	$17
Agios Pharmaceuticals, Inc.	1	$15
Daiichi Sankyo Inc.	1	$15
Amgen	1	$13
Exelixis Inc.	1	$11

Matthew Gall

Payments from drug & device makers

Who reported the general payments

What the payments were tied to

How this compares

Other medical oncology in Burnsville